Ambrisentan
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Undetermined |
Protein binding | 99% |
Elimination half-life | 15 hours (terminal) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C22H22N2O4 |
Molar mass | 378.421 g/mol |
3D model (JSmol) | |
|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
WikiDoc Resources for Ambrisentan |
Articles |
---|
Most recent articles on Ambrisentan Most cited articles on Ambrisentan |
Media |
Powerpoint slides on Ambrisentan |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Ambrisentan at Clinical Trials.gov Clinical Trials on Ambrisentan at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Ambrisentan
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Ambrisentan Discussion groups on Ambrisentan Patient Handouts on Ambrisentan Directions to Hospitals Treating Ambrisentan Risk calculators and risk factors for Ambrisentan
|
Healthcare Provider Resources |
Causes & Risk Factors for Ambrisentan |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Ambrisentan (U.S. trade name Letairis) is a drug being researched for use in the treatment of pulmonary hypertension.
It functions as an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA).[1]
Ambrisentan was approved for sale by the U.S. Food and Drug Administration (FDA) on June 15, 2007 for the once-daily treatment of pulmonary arterial hypertension.[2][3][4] The Marketing Authorisation Application is under review by the European Medicines Agency.[5] Ambrisentan had previously been designated an orphan drug by both the FDA and the European Commission, in August 2004 and May 2005 respectively.[6]
References
- ↑ Vatter H, Seifert V (2006). "Ambrisentan, a non-peptide endothelin receptor antagonist". Cardiovasc Drug Rev. 24 (1): 63–76. PMID 16939634.
- ↑ Pollack, Andrew (2007-06-16). "Gilead's Drug Is Approved to Treat a Rare Disease". New York Times.
- ↑ "U.S. Food and Drug Administration Approves Gilead's Letairis Treatment of Pulmonary Arterial Hypertension" (Press release). Gilead Sciences. 2007-06-15.
- ↑ "FDA Approves New Orphan Drug for Treatment of Pulmonary Arterial Hypertension" (Press release). Food and Drug Administration. 2007-06-15.
- ↑ "Marketing Authorisation Application for Ambrisentan Validated by European Medicines Agency" (Press release). Gilead Sciences. 2007-03-23.
- ↑ Waknine, Yael. "International Approvals: Ambrisentan, Oral-lyn, Risperdal". Medscape.
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Endothelin receptor antagonists
- Gilead Sciences
- Orphan drugs
- Drugs